IL
Illinois House Bill HB0077

Illinois 2025-2026 Regular Session

Illinois House Bill HB0077 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB0077 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED: 720 ILCS 570/208 from Ch. 56 1/2, par. 1208720 ILCS 570/309.1 new Amends the Illinois Controlled Substances Act. Schedules xylazine as a Schedule III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian. LRB104 03201 RLC 13222 b A BILL FOR 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB0077 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED: 720 ILCS 570/208 from Ch. 56 1/2, par. 1208720 ILCS 570/309.1 new 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/309.1 new Amends the Illinois Controlled Substances Act. Schedules xylazine as a Schedule III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian. LRB104 03201 RLC 13222 b LRB104 03201 RLC 13222 b A BILL FOR
22 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB0077 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
33 720 ILCS 570/208 from Ch. 56 1/2, par. 1208720 ILCS 570/309.1 new 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/309.1 new
44 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
55 720 ILCS 570/309.1 new
66 Amends the Illinois Controlled Substances Act. Schedules xylazine as a Schedule III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian.
77 LRB104 03201 RLC 13222 b LRB104 03201 RLC 13222 b
88 LRB104 03201 RLC 13222 b
99 A BILL FOR
1010 HB0077LRB104 03201 RLC 13222 b HB0077 LRB104 03201 RLC 13222 b
1111 HB0077 LRB104 03201 RLC 13222 b
1212 1 AN ACT concerning criminal law.
1313 2 Be it enacted by the People of the State of Illinois,
1414 3 represented in the General Assembly:
1515 4 Section 5. The Illinois Controlled Substances Act is
1616 5 amended by changing Section 208 and by by adding Section 309.1
1717 6 as follows:
1818 7 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
1919 8 (Text of Section before amendment by P.A. 103-881)
2020 9 Sec. 208. (a) The controlled substances listed in this
2121 10 Section are included in Schedule III.
2222 11 (b) Unless specifically excepted or unless listed in
2323 12 another schedule, any material, compound, mixture, or
2424 13 preparation which contains any quantity of the following
2525 14 substances having a stimulant effect on the central nervous
2626 15 system, including its salts, isomers (whether optical
2727 16 position, or geometric), and salts of such isomers whenever
2828 17 the existence of such salts, isomers, and salts of isomers is
2929 18 possible within the specific chemical designation;
3030 19 (1) Those compounds, mixtures, or preparations in
3131 20 dosage unit form containing any stimulant substances
3232 21 listed in Schedule II which compounds, mixtures, or
3333 22 preparations were listed on August 25, 1971, as excepted
3434 23 compounds under Title 21, Code of Federal Regulations,
3535
3636
3737
3838 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026 HB0077 Introduced , by Rep. Jackie Haas SYNOPSIS AS INTRODUCED:
3939 720 ILCS 570/208 from Ch. 56 1/2, par. 1208720 ILCS 570/309.1 new 720 ILCS 570/208 from Ch. 56 1/2, par. 1208 720 ILCS 570/309.1 new
4040 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
4141 720 ILCS 570/309.1 new
4242 Amends the Illinois Controlled Substances Act. Schedules xylazine as a Schedule III controlled substance. Provides that notwithstanding the scheduling of xylazine as a Schedule III controlled substance, xylazine shall not be considered a controlled substance when: (1) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species of a drug containing xylazine that has been approved by the U.S. Food and Drug Administration; (2) used by licensed Illinois veterinarians dispensing or prescribing for, or administering to, a nonhuman species that is permissible under the Federal Food, Drug, and Cosmetic Act; (3) manufactured, distributed, or used as an active pharmaceutical ingredient for manufacturing an animal drug approved under the Federal Food, Drug, and Cosmetic Act; (4) used by a licensed certified euthanasia technician employed by a certified euthanasia agency; or (5) used by a wildlife biologist engaged in legal or authorized fieldwork under the indirect supervision of a veterinarian.
4343 LRB104 03201 RLC 13222 b LRB104 03201 RLC 13222 b
4444 LRB104 03201 RLC 13222 b
4545 A BILL FOR
4646
4747
4848
4949
5050
5151 720 ILCS 570/208 from Ch. 56 1/2, par. 1208
5252 720 ILCS 570/309.1 new
5353
5454
5555
5656 LRB104 03201 RLC 13222 b
5757
5858
5959
6060
6161
6262
6363
6464
6565
6666 HB0077 LRB104 03201 RLC 13222 b
6767
6868
6969 HB0077- 2 -LRB104 03201 RLC 13222 b HB0077 - 2 - LRB104 03201 RLC 13222 b
7070 HB0077 - 2 - LRB104 03201 RLC 13222 b
7171 1 Section 308.32, and any other drug of the quantitative
7272 2 composition shown in that list for those drugs or which is
7373 3 the same except that it contains a lesser quantity of
7474 4 controlled substances;
7575 5 (2) Benzphetamine;
7676 6 (3) Chlorphentermine;
7777 7 (4) Clortermine;
7878 8 (5) Phendimetrazine.
7979 9 (c) Unless specifically excepted or unless listed in
8080 10 another schedule, any material, compound, mixture, or
8181 11 preparation which contains any quantity of the following
8282 12 substances having a potential for abuse associated with a
8383 13 depressant effect on the central nervous system:
8484 14 (1) Any compound, mixture, or preparation containing
8585 15 amobarbital, secobarbital, pentobarbital or any salt
8686 16 thereof and one or more other active medicinal ingredients
8787 17 which are not listed in any schedule;
8888 18 (2) Any suppository dosage form containing
8989 19 amobarbital, secobarbital, pentobarbital or any salt of
9090 20 any of these drugs and approved by the Federal Food and
9191 21 Drug Administration for marketing only as a suppository;
9292 22 (3) Any substance which contains any quantity of a
9393 23 derivative of barbituric acid, or any salt thereof:
9494 24 (3.1) Aprobarbital;
9595 25 (3.2) Butabarbital (secbutabarbital);
9696 26 (3.3) Butalbital;
9797
9898
9999
100100
101101
102102 HB0077 - 2 - LRB104 03201 RLC 13222 b
103103
104104
105105 HB0077- 3 -LRB104 03201 RLC 13222 b HB0077 - 3 - LRB104 03201 RLC 13222 b
106106 HB0077 - 3 - LRB104 03201 RLC 13222 b
107107 1 (3.4) Butobarbital (butethal);
108108 2 (4) Chlorhexadol;
109109 3 (5) Methyprylon;
110110 4 (6) Sulfondiethylmethane;
111111 5 (7) Sulfonethylmethane;
112112 6 (8) Sulfonmethane;
113113 7 (9) Lysergic acid;
114114 8 (10) Lysergic acid amide;
115115 9 (10.1) Tiletamine or zolazepam or both, or any salt of
116116 10 either of them.
117117 11 Some trade or other names for a tiletamine-zolazepam
118118 12 combination product: Telazol.
119119 13 Some trade or other names for Tiletamine:
120120 14 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
121121 15 Some trade or other names for zolazepam:
122122 16 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
123123 17 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
124124 18 (11) Any material, compound, mixture or preparation
125125 19 containing not more than 12.5 milligrams of pentazocine or
126126 20 any of its salts, per 325 milligrams of aspirin;
127127 21 (12) Any material, compound, mixture or preparation
128128 22 containing not more than 12.5 milligrams of pentazocine or
129129 23 any of its salts, per 325 milligrams of acetaminophen;
130130 24 (13) Any material, compound, mixture or preparation
131131 25 containing not more than 50 milligrams of pentazocine or
132132 26 any of its salts plus naloxone HCl USP 0.5 milligrams, per
133133
134134
135135
136136
137137
138138 HB0077 - 3 - LRB104 03201 RLC 13222 b
139139
140140
141141 HB0077- 4 -LRB104 03201 RLC 13222 b HB0077 - 4 - LRB104 03201 RLC 13222 b
142142 HB0077 - 4 - LRB104 03201 RLC 13222 b
143143 1 dosage unit;
144144 2 (14) Ketamine;
145145 3 (15) Thiopental.
146146 4 (d) Nalorphine.
147147 5 (d.5) Buprenorphine.
148148 6 (e) Unless specifically excepted or unless listed in
149149 7 another schedule, any material, compound, mixture, or
150150 8 preparation containing limited quantities of any of the
151151 9 following narcotic drugs, or their salts calculated as the
152152 10 free anhydrous base or alkaloid, as set forth below:
153153 11 (1) not more than 1.8 grams of codeine per 100
154154 12 milliliters or not more than 90 milligrams per dosage
155155 13 unit, with an equal or greater quantity of an isoquinoline
156156 14 alkaloid of opium;
157157 15 (2) not more than 1.8 grams of codeine per 100
158158 16 milliliters or not more than 90 milligrams per dosage
159159 17 unit, with one or more active non-narcotic ingredients in
160160 18 recognized therapeutic amounts;
161161 19 (3) (blank);
162162 20 (4) (blank);
163163 21 (5) not more than 1.8 grams of dihydrocodeine per 100
164164 22 milliliters or not more than 90 milligrams per dosage
165165 23 unit, with one or more active, non-narcotic ingredients in
166166 24 recognized therapeutic amounts;
167167 25 (6) not more than 300 milligrams of ethylmorphine per
168168 26 100 milliliters or not more than 15 milligrams per dosage
169169
170170
171171
172172
173173
174174 HB0077 - 4 - LRB104 03201 RLC 13222 b
175175
176176
177177 HB0077- 5 -LRB104 03201 RLC 13222 b HB0077 - 5 - LRB104 03201 RLC 13222 b
178178 HB0077 - 5 - LRB104 03201 RLC 13222 b
179179 1 unit, with one or more active, non-narcotic ingredients in
180180 2 recognized therapeutic amounts;
181181 3 (7) not more than 500 milligrams of opium per 100
182182 4 milliliters or per 100 grams, or not more than 25
183183 5 milligrams per dosage unit, with one or more active,
184184 6 non-narcotic ingredients in recognized therapeutic
185185 7 amounts;
186186 8 (8) not more than 50 milligrams of morphine per 100
187187 9 milliliters or per 100 grams with one or more active,
188188 10 non-narcotic ingredients in recognized therapeutic
189189 11 amounts.
190190 12 (f) Anabolic steroids, except the following anabolic
191191 13 steroids that are exempt:
192192 14 (1) Androgyn L.A.;
193193 15 (2) Andro-Estro 90-4;
194194 16 (3) depANDROGYN;
195195 17 (4) DEPO-T.E.;
196196 18 (5) depTESTROGEN;
197197 19 (6) Duomone;
198198 20 (7) DURATESTRIN;
199199 21 (8) DUO-SPAN II;
200200 22 (9) Estratest;
201201 23 (10) Estratest H.S.;
202202 24 (11) PAN ESTRA TEST;
203203 25 (12) Premarin with Methyltestosterone;
204204 26 (13) TEST-ESTRO Cypionates;
205205
206206
207207
208208
209209
210210 HB0077 - 5 - LRB104 03201 RLC 13222 b
211211
212212
213213 HB0077- 6 -LRB104 03201 RLC 13222 b HB0077 - 6 - LRB104 03201 RLC 13222 b
214214 HB0077 - 6 - LRB104 03201 RLC 13222 b
215215 1 (14) Testosterone Cyp 50 Estradiol Cyp 2;
216216 2 (15) Testosterone Cypionate-Estradiol Cypionate
217217 3 injection; and
218218 4 (16) Testosterone Enanthate-Estradiol Valerate
219219 5 injection.
220220 6 (g) Hallucinogenic substances.
221221 7 (1) Dronabinol (synthetic) in sesame oil and
222222 8 encapsulated in a soft gelatin capsule in a U.S. Food and
223223 9 Drug Administration approved product. Some other names for
224224 10 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
225225 11 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
226226 12 (-)-delta-9-(trans)-tetrahydrocannabinol.
227227 13 (2) (Reserved).
228228 14 (h) The Department may except by rule any compound,
229229 15 mixture, or preparation containing any stimulant or depressant
230230 16 substance listed in subsection (b) from the application of all
231231 17 or any part of this Act if the compound, mixture, or
232232 18 preparation contains one or more active medicinal ingredients
233233 19 not having a stimulant or depressant effect on the central
234234 20 nervous system, and if the admixtures are included therein in
235235 21 combinations, quantity, proportion, or concentration that
236236 22 vitiate the potential for abuse of the substances which have a
237237 23 stimulant or depressant effect on the central nervous system.
238238 24 (Source: P.A. 100-368, eff. 1-1-18.)
239239 25 (Text of Section after amendment by P.A. 103-881)
240240
241241
242242
243243
244244
245245 HB0077 - 6 - LRB104 03201 RLC 13222 b
246246
247247
248248 HB0077- 7 -LRB104 03201 RLC 13222 b HB0077 - 7 - LRB104 03201 RLC 13222 b
249249 HB0077 - 7 - LRB104 03201 RLC 13222 b
250250 1 Sec. 208. (a) The controlled substances listed in this
251251 2 Section are included in Schedule III.
252252 3 (b) Unless specifically excepted or unless listed in
253253 4 another schedule, any material, compound, mixture, or
254254 5 preparation which contains any quantity of the following
255255 6 substances having a stimulant effect on the central nervous
256256 7 system, including its salts, isomers (whether optical
257257 8 position, or geometric), and salts of such isomers whenever
258258 9 the existence of such salts, isomers, and salts of isomers is
259259 10 possible within the specific chemical designation;
260260 11 (1) Those compounds, mixtures, or preparations in
261261 12 dosage unit form containing any stimulant substances
262262 13 listed in Schedule II which compounds, mixtures, or
263263 14 preparations were listed on August 25, 1971, as excepted
264264 15 compounds under Title 21, Code of Federal Regulations,
265265 16 Section 308.32, and any other drug of the quantitative
266266 17 composition shown in that list for those drugs or which is
267267 18 the same except that it contains a lesser quantity of
268268 19 controlled substances;
269269 20 (2) Benzphetamine;
270270 21 (3) Chlorphentermine;
271271 22 (4) Clortermine;
272272 23 (5) Phendimetrazine.
273273 24 (c) Unless specifically excepted or unless listed in
274274 25 another schedule, any material, compound, mixture, or
275275 26 preparation which contains any quantity of the following
276276
277277
278278
279279
280280
281281 HB0077 - 7 - LRB104 03201 RLC 13222 b
282282
283283
284284 HB0077- 8 -LRB104 03201 RLC 13222 b HB0077 - 8 - LRB104 03201 RLC 13222 b
285285 HB0077 - 8 - LRB104 03201 RLC 13222 b
286286 1 substances having a potential for misuse associated with a
287287 2 depressant effect on the central nervous system:
288288 3 (1) Any compound, mixture, or preparation containing
289289 4 amobarbital, secobarbital, pentobarbital or any salt
290290 5 thereof and one or more other active medicinal ingredients
291291 6 which are not listed in any schedule;
292292 7 (2) Any suppository dosage form containing
293293 8 amobarbital, secobarbital, pentobarbital or any salt of
294294 9 any of these drugs and approved by the Federal Food and
295295 10 Drug Administration for marketing only as a suppository;
296296 11 (3) Any substance which contains any quantity of a
297297 12 derivative of barbituric acid, or any salt thereof:
298298 13 (3.1) Aprobarbital;
299299 14 (3.2) Butabarbital (secbutabarbital);
300300 15 (3.3) Butalbital;
301301 16 (3.4) Butobarbital (butethal);
302302 17 (4) Chlorhexadol;
303303 18 (5) Methyprylon;
304304 19 (6) Sulfondiethylmethane;
305305 20 (7) Sulfonethylmethane;
306306 21 (8) Sulfonmethane;
307307 22 (9) Lysergic acid;
308308 23 (10) Lysergic acid amide;
309309 24 (10.1) Tiletamine or zolazepam or both, or any salt of
310310 25 either of them.
311311 26 Some trade or other names for a tiletamine-zolazepam
312312
313313
314314
315315
316316
317317 HB0077 - 8 - LRB104 03201 RLC 13222 b
318318
319319
320320 HB0077- 9 -LRB104 03201 RLC 13222 b HB0077 - 9 - LRB104 03201 RLC 13222 b
321321 HB0077 - 9 - LRB104 03201 RLC 13222 b
322322 1 combination product: Telazol.
323323 2 Some trade or other names for Tiletamine:
324324 3 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
325325 4 Some trade or other names for zolazepam:
326326 5 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
327327 6 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
328328 7 (11) Any material, compound, mixture or preparation
329329 8 containing not more than 12.5 milligrams of pentazocine or
330330 9 any of its salts, per 325 milligrams of aspirin;
331331 10 (12) Any material, compound, mixture or preparation
332332 11 containing not more than 12.5 milligrams of pentazocine or
333333 12 any of its salts, per 325 milligrams of acetaminophen;
334334 13 (13) Any material, compound, mixture or preparation
335335 14 containing not more than 50 milligrams of pentazocine or
336336 15 any of its salts plus naloxone HCl USP 0.5 milligrams, per
337337 16 dosage unit;
338338 17 (14) Ketamine;
339339 18 (15) Thiopental; .
340340 19 (16) dihydro-4H-1,3 thiazin-2-amine), including its
341341 20 isomers, esters, ethers, salts, and salts of isomers,
342342 21 esters, and ethers, whenever the existence of such
343343 22 isomers, esters, ethers, and salts is possible within the
344344 23 specific chemical designation.
345345 24 (d) Nalorphine.
346346 25 (d.5) Buprenorphine.
347347 26 (e) Unless specifically excepted or unless listed in
348348
349349
350350
351351
352352
353353 HB0077 - 9 - LRB104 03201 RLC 13222 b
354354
355355
356356 HB0077- 10 -LRB104 03201 RLC 13222 b HB0077 - 10 - LRB104 03201 RLC 13222 b
357357 HB0077 - 10 - LRB104 03201 RLC 13222 b
358358 1 another schedule, any material, compound, mixture, or
359359 2 preparation containing limited quantities of any of the
360360 3 following narcotic drugs, or their salts calculated as the
361361 4 free anhydrous base or alkaloid, as set forth below:
362362 5 (1) not more than 1.8 grams of codeine per 100
363363 6 milliliters or not more than 90 milligrams per dosage
364364 7 unit, with an equal or greater quantity of an isoquinoline
365365 8 alkaloid of opium;
366366 9 (2) not more than 1.8 grams of codeine per 100
367367 10 milliliters or not more than 90 milligrams per dosage
368368 11 unit, with one or more active non-narcotic ingredients in
369369 12 recognized therapeutic amounts;
370370 13 (3) (blank);
371371 14 (4) (blank);
372372 15 (5) not more than 1.8 grams of dihydrocodeine per 100
373373 16 milliliters or not more than 90 milligrams per dosage
374374 17 unit, with one or more active, non-narcotic ingredients in
375375 18 recognized therapeutic amounts;
376376 19 (6) not more than 300 milligrams of ethylmorphine per
377377 20 100 milliliters or not more than 15 milligrams per dosage
378378 21 unit, with one or more active, non-narcotic ingredients in
379379 22 recognized therapeutic amounts;
380380 23 (7) not more than 500 milligrams of opium per 100
381381 24 milliliters or per 100 grams, or not more than 25
382382 25 milligrams per dosage unit, with one or more active,
383383 26 non-narcotic ingredients in recognized therapeutic
384384
385385
386386
387387
388388
389389 HB0077 - 10 - LRB104 03201 RLC 13222 b
390390
391391
392392 HB0077- 11 -LRB104 03201 RLC 13222 b HB0077 - 11 - LRB104 03201 RLC 13222 b
393393 HB0077 - 11 - LRB104 03201 RLC 13222 b
394394 1 amounts;
395395 2 (8) not more than 50 milligrams of morphine per 100
396396 3 milliliters or per 100 grams with one or more active,
397397 4 non-narcotic ingredients in recognized therapeutic
398398 5 amounts.
399399 6 (f) Anabolic steroids, except the following anabolic
400400 7 steroids that are exempt:
401401 8 (1) Androgyn L.A.;
402402 9 (2) Andro-Estro 90-4;
403403 10 (3) depANDROGYN;
404404 11 (4) DEPO-T.E.;
405405 12 (5) depTESTROGEN;
406406 13 (6) Duomone;
407407 14 (7) DURATESTRIN;
408408 15 (8) DUO-SPAN II;
409409 16 (9) Estratest;
410410 17 (10) Estratest H.S.;
411411 18 (11) PAN ESTRA TEST;
412412 19 (12) Premarin with Methyltestosterone;
413413 20 (13) TEST-ESTRO Cypionates;
414414 21 (14) Testosterone Cyp 50 Estradiol Cyp 2;
415415 22 (15) Testosterone Cypionate-Estradiol Cypionate
416416 23 injection; and
417417 24 (16) Testosterone Enanthate-Estradiol Valerate
418418 25 injection.
419419 26 (g) Hallucinogenic substances.
420420
421421
422422
423423
424424
425425 HB0077 - 11 - LRB104 03201 RLC 13222 b
426426
427427
428428 HB0077- 12 -LRB104 03201 RLC 13222 b HB0077 - 12 - LRB104 03201 RLC 13222 b
429429 HB0077 - 12 - LRB104 03201 RLC 13222 b
430430 1 (1) Dronabinol (synthetic) in sesame oil and
431431 2 encapsulated in a soft gelatin capsule in a U.S. Food and
432432 3 Drug Administration approved product. Some other names for
433433 4 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
434434 5 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
435435 6 (-)-delta-9-(trans)-tetrahydrocannabinol.
436436 7 (2) (Reserved).
437437 8 (h) The Department may except by rule any compound,
438438 9 mixture, or preparation containing any stimulant or depressant
439439 10 substance listed in subsection (b) from the application of all
440440 11 or any part of this Act if the compound, mixture, or
441441 12 preparation contains one or more active medicinal ingredients
442442 13 not having a stimulant or depressant effect on the central
443443 14 nervous system, and if the admixtures are included therein in
444444 15 combinations, quantity, proportion, or concentration that
445445 16 vitiate the potential for misuse of the substances which have
446446 17 a stimulant or depressant effect on the central nervous
447447 18 system.
448448 19 (Source: P.A. 103-881, eff. 1-1-25.)
449449 20 (720 ILCS 570/309.1 new)
450450 21 Sec. 309.1. Xylazine exemptions. Notwithstanding the
451451 22 scheduling of xylazine as a Schedule III controlled substance,
452452 23 xylazine shall not be considered a controlled substance when:
453453 24 (1) used by licensed Illinois veterinarians dispensing or
454454 25 prescribing for, or administering to, a nonhuman species of a
455455
456456
457457
458458
459459
460460 HB0077 - 12 - LRB104 03201 RLC 13222 b
461461
462462
463463 HB0077- 13 -LRB104 03201 RLC 13222 b HB0077 - 13 - LRB104 03201 RLC 13222 b
464464 HB0077 - 13 - LRB104 03201 RLC 13222 b
465465 1 drug containing xylazine that has been approved by the U.S.
466466 2 Food and Drug Administration;
467467 3 (2) used by licensed Illinois veterinarians dispensing or
468468 4 prescribing for, or administering to, a nonhuman species that
469469 5 is permissible under the Federal Food, Drug, and Cosmetic Act;
470470 6 (3) manufactured, distributed, or used as an active
471471 7 pharmaceutical ingredient for manufacturing an animal drug
472472 8 approved under the Federal Food, Drug, and Cosmetic Act;
473473 9 (4) used by a licensed certified euthanasia technician
474474 10 employed by a certified euthanasia agency; or
475475 11 (5) used by a wildlife biologist engaged in legal or
476476 12 authorized fieldwork under the indirect supervision of a
477477 13 veterinarian.
478478
479479
480480
481481
482482
483483 HB0077 - 13 - LRB104 03201 RLC 13222 b